CN104114686A - Sanfilippo综合征的生物标志物及其用途 - Google Patents
Sanfilippo综合征的生物标志物及其用途 Download PDFInfo
- Publication number
- CN104114686A CN104114686A CN201280065796.8A CN201280065796A CN104114686A CN 104114686 A CN104114686 A CN 104114686A CN 201280065796 A CN201280065796 A CN 201280065796A CN 104114686 A CN104114686 A CN 104114686A
- Authority
- CN
- China
- Prior art keywords
- biomarkers
- level
- sanfilippo syndrome
- treatment
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556810P | 2011-11-07 | 2011-11-07 | |
| US61/556,810 | 2011-11-07 | ||
| US201261584165P | 2012-01-06 | 2012-01-06 | |
| US61/584,165 | 2012-01-06 | ||
| PCT/US2012/063935 WO2013070760A1 (en) | 2011-11-07 | 2012-11-07 | Biomarkers for sanfilippo syndrome and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104114686A true CN104114686A (zh) | 2014-10-22 |
Family
ID=48280853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280065796.8A Pending CN104114686A (zh) | 2011-11-07 | 2012-11-07 | Sanfilippo综合征的生物标志物及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130121984A1 (enExample) |
| EP (1) | EP2776553B1 (enExample) |
| JP (1) | JP2015504514A (enExample) |
| CN (1) | CN104114686A (enExample) |
| AU (1) | AU2012335890A1 (enExample) |
| CA (1) | CA2854333A1 (enExample) |
| WO (1) | WO2013070760A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112578123A (zh) * | 2019-09-27 | 2021-03-30 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015012767A2 (pt) * | 2012-12-07 | 2017-09-12 | Shire Human Genetic Therapies | métodos e composições para tratamento intratecal administrado de mucupolisacaridose tipo iiia |
| AU2015323966A1 (en) * | 2014-09-29 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis IIIB (MPSIIIB) |
| MA40954A (fr) * | 2014-11-14 | 2017-09-19 | Shire Human Genetic Therapies | Détermination de niveaux de glycosaminoglycane par spectrométrie de masse |
| WO2017132675A1 (en) * | 2016-01-29 | 2017-08-03 | Alexion Pharmaceuticals, Inc. | Enzyme replacement therapy in mucopolysaccharidosis iiib patients |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050048047A1 (en) * | 2003-08-29 | 2005-03-03 | Kakkis Emil D. | Delivery of therapeutic compounds to the brain and other tissues |
| US20090092996A1 (en) * | 2005-12-08 | 2009-04-09 | Clarke Lorne A | Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith |
| US20100184013A1 (en) * | 2009-01-02 | 2010-07-22 | Zacharon Pharmaceuticals, Inc. | Detection of oligosaccharides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US20050055733A1 (en) * | 2001-07-06 | 2005-03-10 | Zairen Sun | Small intestine and colon genes |
| US7951545B2 (en) * | 2002-04-30 | 2011-05-31 | Seikagaku Corporation | Method for detecting lysosomal storage diseases |
| AUPS293002A0 (en) * | 2002-06-14 | 2002-07-04 | Women's And Children's Hospital | Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| JP4965999B2 (ja) * | 2005-12-27 | 2012-07-04 | セント ルイス ユニバーシティ | ムコ多糖症の診断方法 |
| WO2010078515A2 (en) * | 2009-01-02 | 2010-07-08 | Zacharon Pharmaceuticals, Inc. | Polymer end group detection |
-
2012
- 2012-11-07 WO PCT/US2012/063935 patent/WO2013070760A1/en not_active Ceased
- 2012-11-07 JP JP2014541200A patent/JP2015504514A/ja active Pending
- 2012-11-07 EP EP12847544.9A patent/EP2776553B1/en active Active
- 2012-11-07 CN CN201280065796.8A patent/CN104114686A/zh active Pending
- 2012-11-07 US US13/671,302 patent/US20130121984A1/en not_active Abandoned
- 2012-11-07 CA CA2854333A patent/CA2854333A1/en not_active Abandoned
- 2012-11-07 AU AU2012335890A patent/AU2012335890A1/en not_active Abandoned
-
2016
- 2016-06-16 US US15/184,731 patent/US20170131293A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050048047A1 (en) * | 2003-08-29 | 2005-03-03 | Kakkis Emil D. | Delivery of therapeutic compounds to the brain and other tissues |
| US20090092996A1 (en) * | 2005-12-08 | 2009-04-09 | Clarke Lorne A | Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith |
| US20100184013A1 (en) * | 2009-01-02 | 2010-07-22 | Zacharon Pharmaceuticals, Inc. | Detection of oligosaccharides |
Non-Patent Citations (2)
| Title |
|---|
| IGOR NESTRASIL ET AL.: "Brain volumes and cognitive function in MPS IIIA: Cross-sectional study", 《MOLECULAR GENETICS AND METABOLISM》, vol. 102, no. 2, 28 February 2011 (2011-02-28) * |
| 赵小媛等: "尿粘多糖定量测定及其临床应用", 《中国儿童保健杂志》, vol. 18, no. 11, 30 November 2010 (2010-11-30) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112578123A (zh) * | 2019-09-27 | 2021-03-30 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途 |
| CN112578123B (zh) * | 2019-09-27 | 2022-10-25 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2776553B1 (en) | 2018-07-11 |
| US20170131293A1 (en) | 2017-05-11 |
| EP2776553A1 (en) | 2014-09-17 |
| JP2015504514A (ja) | 2015-02-12 |
| EP2776553A4 (en) | 2015-05-27 |
| AU2012335890A1 (en) | 2014-05-29 |
| CA2854333A1 (en) | 2013-05-16 |
| WO2013070760A1 (en) | 2013-05-16 |
| US20130121984A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Etter et al. | Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study | |
| EP2776553B1 (en) | Biomarkers for sanfilippo syndrome and uses thereof | |
| JP6707181B2 (ja) | 早産のリスクがある妊娠女性を同定するためのキットまたはパッケージ、および、当該キットまたはパッケージの使用 | |
| CN114410773B (zh) | 用于预测或诊断抑郁症复发的标志物组合及其应用 | |
| US20220057409A1 (en) | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair | |
| EP3327134A1 (en) | Method and biomarkers for in vitro diagnosis of mental disorders | |
| WO2021228125A1 (en) | Protein markers for assessing alzheimer's disease | |
| US20250314645A1 (en) | Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury | |
| JP6663936B2 (ja) | 胎児性アルコール症候群により引き起こされる障害の診断方法 | |
| Cao et al. | Analysis of cases with cerebrospinal fluid characteristics similar to tuberculous meningitis | |
| Epstein et al. | Subventricular zone stem cell niche injury is associated with intestinal perforation in preterm infants and predicts future motor impairment | |
| US8372594B2 (en) | Secreted phospholipase A2 biomarkers for arthritis | |
| US20140221235A1 (en) | Biomarker algorithm for determining the time of stroke symptom onset and method | |
| US20250101519A1 (en) | Use of hypoxia-inducible factor 1 alpha as marker in depression recurrence diagnosis | |
| US20120208718A1 (en) | Schizophrenia treatment response biomarkers | |
| KR102781029B1 (ko) | 경도인지장애 진단을 위한 신규 바이오마커 패널과 알츠하이머 치매 전환 예측 단백질 바이오마커 및 이를 이용한 초기 치매 치료의 최적 환자군 선별을 위한 동반진단용 조성물 | |
| US20250250635A1 (en) | Kit and method for determining presence or absence of affection of dementia | |
| US20150309053A1 (en) | Test method and test kit for psychiatric ailments | |
| Raghavendra et al. | Anubhuti. Can serum biomarkers prognosticate out come of traumatic brain injury (TBI) | |
| KR20240173248A (ko) | 알레르기비염 발생 여부 또는 발생 시기 예측 또는 진단용 조성물, 진단 키트, 정보제공방법 및 알레르기비염 예방 또는 치료제 선별방법 | |
| Isaacs | Pathophysiology and Proteogenomics of Post-infectious and Post-hemorrhagic Hydrocephalus in Infants | |
| WO2022011269A2 (en) | Biofluid-based protein and mirna biomarkers for neonatal hypoxic-ischemic encephalopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141022 |
|
| RJ01 | Rejection of invention patent application after publication |